| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Czech Republic Pharmaceuticals and Healthcare Report Q3 2010
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
Czech Republic |
Published |
14 July 2010 |
Number of Pages |
83 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
File Format |
Discount Offer. Buy 2 Business Monitor Reports and Get 10% off
Discount Offer. Buy 3 Business Monitor Reports and Get 15% off
Discount Offer. Buy 4 Business Monitor Reports and Get 20% off
Discount Offer. Buy 5 Business Monitor Reports and Get 25% off
Discount offer Buy 6 Business Monitor Reports and Get 30% off
Discount Offer. Buy 7-20 Business Monitor Reports and Get 35% off
Discount Offer Buy 21 Business Monitor Reports (or more) and Get 40% off
Discounted price shows in basket.
In the Business Environment Ratings for Emerging Europe in Q310, the Czech Republic retained its pole position, which it climbed to the previous quarter surpassing Greece. The country’s scores in the Risks to Realisation of Returns category, indicating a high degree of operational stability, are somewhat stronger than its Limits of Potential Returns scores, which are brought down by the relatively modest forecast growth of its pharmaceutical market values, as well as some outstanding issues regarding patent protection. The Czech Republic again features in the Pharmaceutical Research and Manufacturers of America (PhRMA)’s Special 301 submission for 2010, with its position being unchanged from 2009. Key areas of concern include pricing and reimbursement regimes (including a therapeutic referencing system that allows patented and non-patented products to be linked for pricing purposes and positive lists), as well as individual physician prescribing budgets (which are compared with historical trends) and general limitations on prescribing more expensive medicines by select specialists.
Nevertheless, the Czech Republic’s pharmaceutical market was calculated to have grown by 9.0% yearon- year (y-o-y) in 2009, in local currency terms, to over CZK79bn (US$4bn). Through to 2014, we expect its value to develop at a compound annual growth rate (CAGR) of 5.83% in local currency terms, reaching CZK105.1bn (US$5.8bn) at consumer prices. This rate of growth will slow to 5.12% over our longer, 10-year forecast period to 2019, partly due to the fact that lower cost generics are expected to increase their share of the total, promoted by government cost containment measures.
On the political front, the Senate elections in October 2010 are expected to further highlight healthcare as an important political arena. In May 2010, the leader of the Civic Democratic Party (ODS), Prime Minister Petr Necas, said the party intends to cut healthcare costs through changes in medicines policy and the promotion of prevention programmes. The party intends to keep the fee structure introduced in 2008 as the state of the public finances means healthcare expenditure is not likely to be increased. The ODS suggested that insurance companies could provide financial incentives to people opting for preventative examinations. In the meantime, the potential for a protracted deadlock following the Chamber of Deputies election in May remains high, which could spook investors. Over the medium term, the extent of the eurozone’s recovery will be the key factor determining the Czech Republic’s growth prospects.
In terms of major company news, in May 2010 a senior consultant at the department of nuclear medicine of the General Teaching Hospital said the Czech Republic planned to produce 5% of the world’s radioisotopes and ensure that they are used for medical purposes, reported the Prague Daily Monitor. Due to the shortage of radioisotopes globally, the Czech Institute of Nuclear Medicine has partnered with the Belgian Institute for Radioisotopes to jointly produce the radioisotopes, in a bid to explore commercial opportunities in this niche area.
Visitor Comments
|
All posts are pre-moderated and must obey the house rules. |
|
Healthcare and Medical Company Profiles
Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.
Competitor Tracking
Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Band-Aid continues its dominance of the US wound care market
US herbal products market grew by 3% through 2012
US analgesics market led by Pfizer's Advil
US emergency contraception market grew by 8% through 2012
US consumer health market to benefit from supplements continuing to perform well
